CoChat

Efficacy and Safety of rAAV2-ND4 Treatment for Leber’s Hereditary Optic Neuropathy

Open access
Wan, Xing, Pei, Han, Zhao, Min-jian, Yang, Shuo, Hu, Wei-kun, He, Heng, Ma, Si-qi, Zhang, Ge, Dong, Xiao-yan, Chen, Chen, Wang, Dao-wen, Li, Bin · 2016 · Scientific Reports

The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.

Abstract

Leber’s hereditary optic neuropathy (LHON) is a mitochondrially inherited disease leading to blindness. A mitochondrial DNA point mutation at the 11778 nucleotide site of the NADH dehydrogenase subunit 4 ( ND4 ) gene is the most common cause. The aim of this study was to evaluate the efficacy and safety of a recombinant adeno-associated virus 2 (AAV2) carrying ND4 (rAAV2-ND4) in LHON patients carrying the G11778A mutation. Nine patients were administered rAAV2-ND4 by intravitreal injection to one eye and then followed for 9 months. Ophthalmologic examinations of visual acuity, visual field and optical coherence tomography were performed. Physical examinations included routine blood and urine. The visual acuity of the injected eyes of six patients improved by at least 0.3 log MAR after 9 months of follow-up. In these six patients, the visual field was enlarged but the retinal nerve fibre layer remained relatively stable. No other outcome measure was significantly changed. None of the nine patients had local or systemic adverse events related to the vector during the 9-month follow-up period. These findings support the feasible use of gene therapy for LHON.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/srep21587

Cites

31 of 31 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Retinal appearance and morphologic features before and after intravitreal injection of rAAV2- ND4 in the nine patients. (A) Representative 30° fundus photographs taken with a NIDEK Auto Fundus Camera show the disk and macula of injected eyes of patients before intravitreal injection. The retinal structure of the nine patients was normal. (B to E) 30° fundus photographs show the disk and macula of injected eyes of the nine patients at months 1, 3, 6, and 9 after intravitreal injection, respectively. No apparent retinal abnormality was found.
Figure 1 Retinal appearance and morphologic features before and after intravitreal injection of rAAV2- ND4 in the nine patients. (A) Representative 30° fundus photographs taken with a NIDEK Auto Fundus Camera show the disk and macula of injected eyes of patients before intravitreal injection. The retinal structure of the nine patients was normal. (B to E) 30° fundus photographs show the disk and macula of injected eyes of the nine patients at months 1, 3, 6, and 9 after intravitreal injection, respectively. No apparent retinal abnormality was found.CC BY · PubMed Central
Figure 2 Visual acuity (log MAR) before and after intravitreal injection of rAAV2- ND4 in the nine patients. Mean best-corrected visual acuity (BCVA) values of injected and uninjected eyes before and 1, 3, 6 and 9 months after intravitreal injection are shown.
Figure 2 Visual acuity (log MAR) before and after intravitreal injection of rAAV2- ND4 in the nine patients. Mean best-corrected visual acuity (BCVA) values of injected and uninjected eyes before and 1, 3, 6 and 9 months after intravitreal injection are shown.CC BY · PubMed Central
Figure 3 Visual field of the injected eye of patient 4 at the 9-month follow-up. The visual field of the injected eye of patient 4 was gradually improved at 1, 3, 6, and 9 months after treatment, and the visual field at 6 months after treatment was the best.
Figure 3 Visual field of the injected eye of patient 4 at the 9-month follow-up. The visual field of the injected eye of patient 4 was gradually improved at 1, 3, 6, and 9 months after treatment, and the visual field at 6 months after treatment was the best.CC BY · PubMed Central
Figure 4 Visual field index (VFI) of injected and uninjected eyes of the nine patients. Mean VFI values of injected and uninjected eyes before and 1, 3, 6 and 9 months after intravitreal injection are shown. Eight patients had their VFI improved after treatment; the VFI of patient 5 was not improved.
Figure 4 Visual field index (VFI) of injected and uninjected eyes of the nine patients. Mean VFI values of injected and uninjected eyes before and 1, 3, 6 and 9 months after intravitreal injection are shown. Eight patients had their VFI improved after treatment; the VFI of patient 5 was not improved.CC BY · PubMed Central
Figure 5 Mean defect (MD) of injected and uninjected eyes of the nine patients. Mean MD values of injected and uninjected eyes before and 1, 3, 6, and 9 months after intravitreal injection.
Figure 5 Mean defect (MD) of injected and uninjected eyes of the nine patients. Mean MD values of injected and uninjected eyes before and 1, 3, 6, and 9 months after intravitreal injection.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 31 references

Research works printed but not linked: 2

  1. Pei, H., Wan, X., Hu, W., Dong, X. & Li, B. Constructing and detecting a new rAAV2/2-ND4. Eye Science 28, 55–59 (2013).
  2. Gao, J. et al. Comparison of immunosuppressive effects and ND4 expression among different immunosuppressive strategies following AAV2-ND4 gene treatment for Leber hereditary optic neuropathy. J. Huazhong Acta Med. Univ. Sci. Tech. 42, 187–191 (2013).

Cited by

See all 182

Metadata

Authors
Wan, X., Pei, H., Zhao, M.-J., Yang, S., Hu, W.-K., He, H., Ma, S.-Q., Zhang, G., Dong, X.-Y., Chen, C., Wang, D.-W., & Li, B.
Affiliations
  • Tongji Hospital (CN)
  • Ezhou Central Hospital (CN)
  • Sun Yat-sen University (CN)
Corresponding author
Li, Bin
Venue
Scientific Reports
Published
2016-02-19
Volume
6
Issue
1
Pages
21587-21587
ISSN
2045-2322 (ISSN-L)
OpenAlex
W2397855699
Cited by
182
References
31
Citations by year
2026: 10 · 2025: 14 · 2024: 9 · 2023: 16 · 2022: 21 · 2021: 19 · 2020: 19 · 2019: 21 · 2018: 21 · 2017: 17 · 2016: 13
FWCI
19.33
Type
journal article
Language
en
Open access
Licence
Locations
  • Scientific Reports (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
Funders
  • National Natural Science Foundation of China (30872823, 30801260, 2010021, 81271015)
  • Tongji University
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
  • Health Sciences › Medicine › Ophthalmology › Retinal Development and Disorders
  • Health Sciences › Medicine › Ophthalmology › Glaucoma and retinal disorders
Keywords
Leber's hereditary optic neuropathy, NADH dehydrogenase subunit 4, mitochondrial DNA mutations, intravitreal injection, visual acuity, visual field, retinal nerve fiber layer, treatment safety, mitochondrial disease
MeSH terms
Dependovirus, Administration, Oral, Adolescent, Adult, Child, Electroretinography, Female, Follow-Up Studies, Humans, Male, Middle Aged, Mutation, NADH Dehydrogenase, Plasmids, Prednisolone, Genetic Therapy, Treatment Outcome, Point Mutation, Optic Atrophy, Hereditary, Leber, Tomography, Optical Coherence, Young Adult, HEK293 Cells, Intravitreal Injections

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Efficacy and Safety of rAAV2-ND4 Treatment for Leber’s Hereditary Optic Neuropathy. https://app.cochat.ai/papers/10.1038/srep21587
The paper
Wan, X., Pei, H., Zhao, M.-J., Yang, S., Hu, W.-K., He, H., Ma, S.-Q., Zhang, G., Dong, X.-Y., Chen, C., Wang, D.-W., & Li, B. (2016). Efficacy and Safety of rAAV2-ND4 Treatment for Leber’s Hereditary Optic Neuropathy. Scientific Reports. https://doi.org/10.1038/srep21587

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.